Haematological and Nutritional Prognostic Biomarkers for Patients Receiving CROSS or FLOT

Overview

Journal J Gastrointest Oncol

Date 2023 May 18

PMID 37201072

Authors

Nicholas McNamee

Udit Nindra

Adel Shahnam

Robert Yoon

Ray Asghari

Weng Ng

Deme Karikios

Mark Wong

Affiliations

Soon will be listed here.

Abstract

Background: Neoadjuvant carboplatin and paclitaxel with radiotherapy (CROSS) and perioperative docetaxel, oxaliplatin, calcium folinate and fluorouracil (FLOT) are widely used for gastric (GC), gastro-oesophageal junction (GOJ) and oesophageal cancers (OC). Prognostic and predictive markers for response and survival outcomes are lacking. This study evaluates dynamic neutrophil-lymphocyte ratios (NLR), platelet-lymphocyte ratios (PLR), albumin and body mass index (BMI) as predictors of survival, response and toxicity.

Methods: This multi-centre retrospective observational study across 5 Sydney hospitals included patients receiving CROSS or FLOT from 2015 to 2021. Haematological results and BMI were recorded at baseline and pre-operatively, and after adjuvant treatment for FLOT. Toxicities were also recorded. An NLR ≥2 and PLR ≥200 was used to stratify patients. Univariate and multivariate analyses were performed to determine predictors of overall survival (OS), disease free survival (DFS), rates of pathological complete response (pCR) and toxicity.

Results: One hundred sixty-eight patients were included (95 FLOT, 73 FLOT). A baseline NLR ≥2 was predictive for worse DFS (HR 2.78, 95% CI: 1.41-5.50, P<0.01) and OS (HR 2.90, 95% CI: 1.48-5.67, P<0.01). Sustained elevation in NLR was predictive for DFS (HR 1.54, 95% CI: 1.08-2.17, P=0.01) and OS (HR 1.65, 95% CI: 1.17-2.33, P<0.01). An NLR ≥2 correlated with worse pCR rates (16% for NLR ≥2, 48% for NLR <2, P=0.04). A baseline serum albumin <33 was predictive of worse DFS and OS with a HR of 6.17 (P=0.01) and 4.66 (P=0.01) respectively. Baseline PLR, BMI, and dynamic changes in these markers were not associated with DFS, OS or pCR rates. There was no association of the aforementioned variables with toxicity.

Conclusions: This demonstrates that a high inflammatory state represented by an NLR ≥2, both at baseline and sustained, is prognostic and predictive of response in patients receiving FLOT or CROSS. Baseline hypoalbuminaemia is predictive of poorer outcomes.

Citing Articles

Deep Learning Histology for Prediction of Lymph Node Metastases and Tumor Regression after Neoadjuvant FLOT Therapy of Gastroesophageal Adenocarcinoma.

Jung J, Pisula J, Beyerlein X, Lukomski L, Knipper K, Abu Hejleh A Cancers (Basel). 2024; 16(13).

PMID: 39001507 PMC: 11240557. DOI: 10.3390/cancers16132445.

References

Pang W, Lou N, Jin C, Hu C, Arvine C, Zhu G . Combination of preoperative platelet/lymphocyte and neutrophil/lymphocyte rates and tumor-related factors to predict lymph node metastasis in patients with gastric cancer. Eur J Gastroenterol Hepatol. 2016; 28(5):493-502. PMC: 4892768. DOI: 10.1097/MEG.0000000000000563. View

Owens R, Cox C, Gomberg S, Pan S, Radhakrishna G, Parikh S . Outcome of Weekly Carboplatin-Paclitaxel-based Definitive Chemoradiation in Oesophageal Cancer in Patients Not Considered to be Suitable for Platinum-Fluoropyrimidine-based Treatment: A Multicentre, Retrospective Review. Clin Oncol (R Coll Radiol). 2019; 32(2):121-130. DOI: 10.1016/j.clon.2019.09.058. View

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

Deans D, Wigmore S, de Beaux A, Paterson-Brown S, Garden O, Fearon K . Clinical prognostic scoring system to aid decision-making in gastro-oesophageal cancer. Br J Surg. 2007; 94(12):1501-8. DOI: 10.1002/bjs.5849. View

Li K, Xia X, Su M, Zhang H, Chen W, Zou C . Predictive value of lymphocyte-to-monocyte ratio (LMR) and neutrophil-to-lymphocyte ratio (NLR) in patients with oesophageal cancer undergoing concurrent chemoradiotherapy. BMC Cancer. 2019; 19(1):1004. PMC: 6815405. DOI: 10.1186/s12885-019-6157-4. View

Rinninella E, Strippoli A, Cintoni M, Raoul P, Vivolo R, Di Salvatore M . Body Composition Changes in Gastric Cancer Patients during Preoperative FLOT Therapy: Preliminary Results of an Italian Cohort Study. Nutrients. 2021; 13(3). PMC: 7999770. DOI: 10.3390/nu13030960. View

Wagener-Ryczek S, Schoemmel M, Kraemer M, Bruns C, Schroeder W, Zander T . Immune profile and immunosurveillance in treatment-naive and neoadjuvantly treated esophageal adenocarcinoma. Cancer Immunol Immunother. 2020; 69(4):523-533. PMC: 7113210. DOI: 10.1007/s00262-019-02475-w. View

Shamamian P, Schwartz J, Pocock B, Monea S, Whiting D, Marcus S . Activation of progelatinase A (MMP-2) by neutrophil elastase, cathepsin G, and proteinase-3: a role for inflammatory cells in tumor invasion and angiogenesis. J Cell Physiol. 2001; 189(2):197-206. DOI: 10.1002/jcp.10014. View

Booka E, Kikuchi H, Haneda R, Soneda W, Kawata S, Murakami T . Neutrophil-to-Lymphocyte Ratio to Predict the Efficacy of Immune Checkpoint Inhibitor in Upper Gastrointestinal Cancer. Anticancer Res. 2022; 42(6):2977-2987. DOI: 10.21873/anticanres.15781. View

10.

Huh S, Liang S, Sharma A, Dong C, Robertson G . Transiently entrapped circulating tumor cells interact with neutrophils to facilitate lung metastasis development. Cancer Res. 2010; 70(14):6071-82. PMC: 2905495. DOI: 10.1158/0008-5472.CAN-09-4442. View

11.

Powell A, Chin C, Coxon A, Chalishazar A, Christian A, Roberts S . Neutrophil to lymphocyte ratio as a predictor of response to neoadjuvant chemotherapy and survival in oesophageal adenocarcinoma. BJS Open. 2020; 4(3):416-423. PMC: 7260416. DOI: 10.1002/bjs5.50277. View

12.

Jagadesham V, Lagarde S, Immanuel A, Griffin S . Systemic inflammatory markers and outcome in patients with locally advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction. Br J Surg. 2017; 104(4):401-407. DOI: 10.1002/bjs.10425. View

13.

Le Roy B, Pereira B, Bouteloup C, Costes F, Richard R, Selvy M . Effect of prehabilitation in gastro-oesophageal adenocarcinoma: study protocol of a multicentric, randomised, control trial-the PREHAB study. BMJ Open. 2016; 6(12):e012876. PMC: 5168676. DOI: 10.1136/bmjopen-2016-012876. View

14.

Al-Batran S, Homann N, Pauligk C, Goetze T, Meiler J, Kasper S . Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma.... Lancet. 2019; 393(10184):1948-1957. DOI: 10.1016/S0140-6736(18)32557-1. View

15.

Crumley A, McMillan D, McKernan M, Going J, Shearer C, Stuart R . An elevated C-reactive protein concentration, prior to surgery, predicts poor cancer-specific survival in patients undergoing resection for gastro-oesophageal cancer. Br J Cancer. 2006; 94(11):1568-71. PMC: 2361311. DOI: 10.1038/sj.bjc.6603150. View

16.

den Boer R, Jones K, Ash S, van Boxel G, Gillies R, ODonnell T . Impact on postoperative complications of changes in skeletal muscle mass during neoadjuvant chemotherapy for gastro-oesophageal cancer. BJS Open. 2020; 4(5):847-854. PMC: 7528528. DOI: 10.1002/bjs5.50331. View

17.

Rice T, Ishwaran H, Blackstone E, Hofstetter W, Kelsen D, Apperson-Hansen C . Recommendations for clinical staging (cTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals. Dis Esophagus. 2016; 29(8):913-919. PMC: 5591442. DOI: 10.1111/dote.12540. View

18.

Mak M, Bell K, Ng W, Lee M . Nutritional status, management and clinical outcomes in patients with esophageal and gastro-oesophageal cancers: A descriptive study. Nutr Diet. 2017; 74(3):229-235. DOI: 10.1111/1747-0080.12306. View

19.

Davern M, Donlon N, Sheppard A, O Connell F, Hayes C, Bhardwaj A . Chemotherapy regimens induce inhibitory immune checkpoint protein expression on stem-like and senescent-like oesophageal adenocarcinoma cells. Transl Oncol. 2021; 14(6):101062. PMC: 8008239. DOI: 10.1016/j.tranon.2021.101062. View

20.

Jemal A, Bray F, Center M, Ferlay J, Ward E, Forman D . Global cancer statistics. CA Cancer J Clin. 2011; 61(2):69-90. DOI: 10.3322/caac.20107. View